Why in the news?
The first successful clinical demonstration of RNA editing in humans was conducted.
More on the news
- Wave Life Sciences (US based biotechnology company) has successfully performed RNA editing to treat alpha-1 antitrypsin deficiency (AATD, an inherited disorder).
- In AATD, levels of protein α-1 antitrypsin build up and affect liver and lungs.
About RNA (Ribonucleic acid) Editing
- It is a process that modifies genetic information on RNA sequences through insertion, deletion or substitution.
- Scientists used technique called ‘Adenosine Deaminase Acting on RNA (ADAR)’ with guide RNA (gRNA). (refer image)
- GRNA are small RNA molecules that direct editing machinery by base-pairing with mRNA in specific regions for modification.
- Process
- RNA has four building blocks: A (Adenine), G (Guanine), U (Uracil), and C (Cytosine).
- ADAR converts adenosine in mRNA to inosine, which mimics function of guanosine. (adenosine and guanosine are nucleosides combining A and G with ribose respectively).
- Cell detects Inosine in Adenosine’s position, triggering cellular response to correct the mismatch.
- The process thus restores mRNA’s original function, and cell starts making normal proteins.
- Challenges in RNA Editing: Lack of Specificity and Transient nature and nascent stage of development
Comparison between RNA and DNA editing
|
